• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮射频消融术与肾部分切除术治疗肾细胞癌:最常见亚型的透明细胞和非透明细胞的长期肿瘤学结果比较

Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype.

作者信息

Liu Ning, Huang Daoguang, Cheng Xiangming, Chong Yankun, Wang Wei, Gan Weidong, Guo Hongqian

机构信息

Department of Urology, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu Province, People's Republic of China.

Department of Urology, Lichuan People's Hospital, Lichuan, Hubei Province, People's Republic of China.

出版信息

Urol Oncol. 2017 Aug;35(8):530.e1-530.e6. doi: 10.1016/j.urolonc.2017.03.014. Epub 2017 Apr 10.

DOI:10.1016/j.urolonc.2017.03.014
PMID:28408296
Abstract

OBJECTIVES

To compare the clinical outcomes of percutaneous radiofrequency ablation (PRFA) and partial nephrectomy (PN) in patients with clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) of the most common subtypes.

MATERIALS AND METHODS

A retrospective study was conducted to review the records of all the patients who underwent PRFA or PN between February 2005 and April 2014 at our institution. Patients with histologic confirmation of ccRCC, papillary RCC, and chromophobe RCC were included. The Mann-Whitney U test was applied to compare PRFA to PN in the ccRCC and nccRCC groups. The Kaplan-Meier method was used to generate the survival curves that were compared to the log-rank test.

RESULTS

A total of 264 patients meeting the selection criteria were included in this study. The tumor size ranged from 0.9 to 7.0cm. The median follow-up period was 78 months (range: 8-132 mo). Although PRFA provided comparable 10-year overall survival rates and 10-year disease-free survival (DFS) rates to PN both in ccRCC ≤4cm and nccRCC, the 10-year DFS for patients treated with PRFA was lower than that of PN in ccRCC >4cm. The DFS survival curve between the 2 operations and 2 subtypes was statistically significant in patients with tumor size >4cm. Limitations include retrospective review and selection bias.

CONCLUSIONS

Patients with T1b ccRCC treated with PRFA have less favorable outcomes than those with PN whereas PRFA provides comparable oncologic outcomes to PN in patients with T1b nccRCC. It is necessary to take RCC subtypes into consideration when choosing a surgical approach to treat T1b RCC between PFRA and PN.

摘要

目的

比较经皮射频消融术(PRFA)和部分肾切除术(PN)治疗最常见亚型的透明细胞肾细胞癌(ccRCC)和非透明细胞肾细胞癌(nccRCC)患者的临床结局。

材料与方法

进行一项回顾性研究,以查阅2005年2月至2014年4月在本机构接受PRFA或PN治疗的所有患者的记录。纳入经组织学证实为ccRCC、乳头状RCC和嫌色细胞RCC的患者。采用Mann-Whitney U检验比较ccRCC组和nccRCC组中PRFA与PN的情况。使用Kaplan-Meier方法生成生存曲线,并与对数秩检验进行比较。

结果

本研究共纳入264例符合选择标准的患者。肿瘤大小范围为0.9至7.0cm。中位随访期为78个月(范围:8 - 132个月)。尽管在ccRCC≤4cm和nccRCC中,PRFA的10年总生存率和10年无病生存率(DFS)与PN相当,但在ccRCC>4cm时,接受PRFA治疗患者的10年DFS低于PN。在肿瘤大小>4cm的患者中,两种手术方式和两种亚型之间的DFS生存曲线具有统计学意义。局限性包括回顾性研究和选择偏倚。

结论

PRFA治疗的T1b ccRCC患者的结局不如PN治疗的患者,而PRFA在T1b nccRCC患者中提供了与PN相当的肿瘤学结局。在选择PFRA和PN治疗T1b RCC的手术方式时,有必要考虑RCC亚型。

相似文献

1
Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype.经皮射频消融术与肾部分切除术治疗肾细胞癌:最常见亚型的透明细胞和非透明细胞的长期肿瘤学结果比较
Urol Oncol. 2017 Aug;35(8):530.e1-530.e6. doi: 10.1016/j.urolonc.2017.03.014. Epub 2017 Apr 10.
2
Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.射频消融与部分肾切除术治疗单发临床 T1a 期肾细胞癌患者:至少 5 年随访的可比肿瘤学结果。
Eur Urol. 2012 Jun;61(6):1156-61. doi: 10.1016/j.eururo.2012.01.001. Epub 2012 Jan 10.
3
Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.对于病理分期为T1a期的肾细胞癌患者,行部分肾切除术后需要考虑组织学亚型:乳头状肾细胞癌与透明细胞肾细胞癌。
J Cancer Res Clin Oncol. 2017 Sep;143(9):1845-1851. doi: 10.1007/s00432-017-2430-6. Epub 2017 Apr 27.
4
Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses.部分肾切除术与经皮消融术治疗 cT1 期肾肿瘤的比较。
Eur Urol. 2015 Feb;67(2):252-9. doi: 10.1016/j.eururo.2014.07.021. Epub 2014 Aug 6.
5
Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy.经皮射频消融是治疗小肾肿瘤的有效方法,与部分肾切除术相当。
Eur Radiol. 2023 Nov;33(11):7371-7379. doi: 10.1007/s00330-023-09779-7. Epub 2023 Jun 6.
6
Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.cT1-2/N0/M0期透明细胞肾细胞癌行微创部分肾切除术与微创根治性肾切除术的肿瘤学结局:一项倾向评分匹配分析
World J Urol. 2017 May;35(5):789-794. doi: 10.1007/s00345-016-1923-2. Epub 2016 Aug 30.
7
Radiofrequency ablation versus partial nephrectomy for clinical T1a renal-cell carcinoma: long-term clinical and oncologic outcomes based on a propensity score analysis.临床T1a期肾细胞癌的射频消融与部分肾切除术:基于倾向评分分析的长期临床和肿瘤学结果
J Endourol. 2015 May;29(5):518-25. doi: 10.1089/end.2014.0864. Epub 2015 Feb 18.
8
Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.射频消融治疗 T1 期肾细胞癌的长期肿瘤学结果。
Eur Urol. 2013 Mar;63(3):486-92. doi: 10.1016/j.eururo.2012.08.062. Epub 2012 Sep 5.
9
Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.非透明细胞肾细胞癌患者临床试验治疗的生存结局综合分析。
Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
10
Cryoablation versus Partial Nephrectomy for Clinical T1b Renal Tumors: A Matched Group Comparative Analysis.冷冻消融与部分肾切除术治疗 T1b 期临床肾肿瘤:匹配组对比分析。
Eur Urol. 2017 Jan;71(1):111-117. doi: 10.1016/j.eururo.2016.08.039. Epub 2016 Aug 25.

引用本文的文献

1
Surgical Management of Renal Cell Carcinoma in Transplanted Kidneys-A Narrative Review.移植肾肾细胞癌的外科治疗——一项叙述性综述
Cancers (Basel). 2025 May 31;17(11):1864. doi: 10.3390/cancers17111864.
2
Risk-adjusted trifecta outcomes in ultrasound-guided RFA of T1a renal masses: experi-ence from a large tertiary cancer center.T1a期肾肿块超声引导下射频消融术的风险调整三联征结局:来自大型三级癌症中心的经验
Int Braz J Urol. 2025 Jul-Aug;51(4). doi: 10.1590/S1677-5538.IBJU.2025.0034.
3
Minimally Invasive Salvage Approaches for Management of Recurrence After Primary Renal Mass Ablation.
原发性肾肿瘤消融术后复发管理的微创挽救治疗方法
Cancers (Basel). 2025 Mar 13;17(6):974. doi: 10.3390/cancers17060974.
4
Partial nephrectomy versus radiofrequency ablation in patients with cT1a renal cell carcinoma: A surveillance, epidemiology, end results (SEER) analysis.部分肾切除术与射频消融术治疗 cT1a 期肾细胞癌患者的比较:监测、流行病学和最终结果(SEER)分析。
Medicine (Baltimore). 2024 Nov 29;103(48):e40721. doi: 10.1097/MD.0000000000040721.
5
Image-Guided Ablation of Renal Masses: Challenges to Produce High-Quality Evidence and Future Directions.图像引导下肾肿块消融:生成高质量证据面临的挑战及未来方向
Semin Intervent Radiol. 2024 Jul 10;41(2):144-153. doi: 10.1055/s-0044-1787163. eCollection 2024 Apr.
6
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms.cT1a期非透明细胞肾细胞癌局部肿瘤破坏与部分肾切除术的长期结局及预后列线图的制定
J Cancer Res Clin Oncol. 2024 Mar 12;150(3):122. doi: 10.1007/s00432-023-05571-8.
7
Treatment strategies for clear cell renal cell carcinoma: Past, present and future.透明细胞肾细胞癌的治疗策略:过去、现在与未来
Front Oncol. 2023 Mar 21;13:1133832. doi: 10.3389/fonc.2023.1133832. eCollection 2023.
8
Long-term outcomes of radiofrequency ablation vs. partial nephrectomy for cT1 renal cancer: A meta-analysis and systematic review.射频消融术与部分肾切除术治疗cT1期肾癌的长期疗效:一项荟萃分析与系统评价
Front Surg. 2023 Jan 6;9:1012897. doi: 10.3389/fsurg.2022.1012897. eCollection 2022.
9
Analgesic effects of dexmedetomidine and remifentanil on periprocedural pain during percutaneous ablation of renal carcinoma.右美托咪定和瑞芬太尼对肾肿瘤经皮消融围手术期疼痛的镇痛效果。
Ups J Med Sci. 2020 Feb;125(1):52-57. doi: 10.1080/03009734.2020.1720047. Epub 2020 Feb 18.
10
The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.尿毒症毒素对甲酚硫酸酯通过 microRNA-21/HIF-1α 轴信号诱导透明细胞肾细胞癌的增殖和迁移。
Sci Rep. 2019 Mar 1;9(1):3207. doi: 10.1038/s41598-019-39646-9.